purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation opk earnings call period ending march image source motley fool opko health opk q earnings callmay pm etcontents prepared remark question answer call participant prepared remark operatorhello welcome opko health firstquarter financial result conference call operator instruction please note event recorded would like turn conference host today yvonne briggs please go aheadyvonne briggs investor relation thank operator good afternoon yvonne briggs lha thank joining today call discus opko health financial result first quarter would like remind statement made call management statement historical fact considered forwardlooking subject risk uncertainty materially affect company expected result forwardlooking statement include without limitation various risk described company sec filing including annual report form k year ended december st subsequently filed sec report conference call contains timesensitive information accurate date live broadcast may th except required law opko undertakes obligation revise update forwardlooking statement reflect event circumstance date call begin let review format today calldr phillip frost chairman chief executive officer open call dr elia zerhouni vice chairman president provide overview bioreference health followed opkos pharmaceutical business adam logal opkos cfo review company firstquarter financial result open call question would like turn call dr frost phillip frost chairman chief executive officer good afternoon thank joining u today march announced agreement sell certain asset bioreference health labcorp million asset included bioreferences clinical diagnostics woman health testing service outside new york new jersey transaction specifically structured manner increase likelihood obtaining expedited clearance antitrust regulator also streamlines remaining operation advance path profitability diagnostic segment transaction expected close second half year pending ftc clearance general longacting growth hormone therapy continues gain traction global commercial partner pfizer expands launch product global market onceweekly injection product treat growth hormone deficiency first new chemical entity developed opko biologics israel preclinical candidate development one longacting form oxyntomodulin analog mentioned last quarterly call pegylated form active peptide shown effective safe treating diabetes obesity phase study patient new longacting form expected pharmacology profile pegylated form permit administering larger dos development longacting hgh antagonist treatment acromegaly caused excessive secretion growth hormone igf progressing work enteron bio develop oral form oxyntomodulin glp analog short bowel syndrome disorder involving nutrient malabsorption look forward keep apprised progress promising program modex continues advance development work two program track enter clinic year epsteinbarr vaccine licensed merck multispecific oncology antibody received fda clearance phase trial collaboration barda moving forward provides nondilutive financing develop multispecific antibody covid work progress first indication begin explore alternative target tackle biodefense threat influenza brief overview turn elia eliaselias zerhouni vice chairman president well thank phil good afternoon everyone let start apologizing hear background noise noisy environment airport phil said pleased announce agreement labcorp sell certain asset bioreference health cash purchase price million asset generate approximately million annual revenue include patient service standard certain customer contract operating asset associated testing service focused clinical diagnostics woman health across yous outside new york new jersey retain national oncology urology franchise diagnostic service new york new jersey complement effort improve efficiency enhance productivity operation transaction streamline laboratory service business support work reestablish profitability near future phil mentioned expect sale close second half subject customary closing condition applicable regulatory approval ongoing initiative continue improve bioreferences performance turn build value focus remains initiative reduce cost improve efficiency enhance productivity addition seek bolster growth expansion insurance coverage higher value specialty segment oncology urology particular focus proprietary kscore test know kscore test first introduced laboratorydeveloped test know fda published new rule reform regulation labdeveloped test minimal impact bioreference health test approved new york state regulator exempted announced fda reform december would like remind kscore approved fda supported analytical clinical data fda concluded kscore test appropriate sensitivity negative predictive value contribute overall beneficial clinical decision whether prostate biopsy performed accordingly minimize unnecessary biopsy without excess risk missing clinically significant prostate cancer independent publication urologist since kscore ranked bestperforming biomarker test assessment risk probability aggressive prostate cancer urology team delivers strong growth kscore test volume first quarter expect volume build test included various clinical guideline early detection prostate cancer followup psa screening initial repeat biopsy risk stratification regard rayaldee program continues enjoy stable demand hope grow new data rayaldee may delay onset dialysis according recent analysis oncology pleased genpaths performance due innovative testing platform expanded hematological malignancy panel competitive turnaround time continue see strong growth oncology business growth volume q versus q much growth collaboration large cancer center midlevel health system health system challenged cost staffing oncology space looking reference laboratory work testing opening possibility bioreference health genpath able meet need enhanced comprehensive menu across stage care includes internalization hereditary cancer business late q offer client internal solution fast turnaround time timely decisionmaking continue expand testing portfolio expect new test q complement current oncocyte advance oncorisk portfolio enable genpath oncology evaluate guidelinerecommended genetic component prostate cancer keep u forefront precision oncology similar new york new jersey woman health clinical business national oncology testing segment remain bioreference health genpath oncology brand upon closing transaction nacor believe bioreference health wellpositioned expense reduction revenue expansion focus retained business new york new jersey market divestiture complementing effort boost performance continue improve diagnostic division enhance profitability opko health best position u innovative biopharmaceutical company moving pharmaceutical segment heard ngenla launched major global market like pfizer believe drug wellpositioned significant growth longacting growth hormone product become global standard treating growth hormone deficiency child launch progressing expected increasing significant percentage patient shifting daily longacting week ngenla product addition expect partnership pfizer expand additional indication including growth hormone deficiency adult pediatric application combined approval two indication entitle opko additional million milestone payment let go modex modex proud progress date march announced favorable result phase clinical study trispecific antibody hiv clinical data first reported trispecific antibody human strongly support development multispecific multivalent antibody hiv antibody found safe well tolerated dose level intravenous subcutaneous route minimal antidrug antibody observed dosing ranging milligram per kilogram milligram per kilogram four administration pharmacokinetic remained consistent similar standard molecular antibody therefore believe partner nih believe multispecific antibody offer differentiated approach longlasting preventive therapeutic option hiv variant possibility activating immune system latent virus population affect functional cure partner nih program collaboration merck develop mdx epsteinbarr virus multivalent nanoparticle vaccine advancing plan received million upfront payment upon licensing vaccine potential million development commercial milestone plus royalty global sale ranging singledigit doubledigit percentage term timing expect program enter clinic later part year collaboration barda also proceeding schedule represents another source nondilutive funding company secured initial million grant fund rd clinical evaluation phase study multispecific antibody known variant sarscov treatment prevention covid additional funding million may available barda develop multispecific antibody delivery approach target biodefense threat influenza ultimate goal research program develop platform genebased delivery method using mrna dna vector supplement body natural protein production process used efficiently effectively future pandemic rounding modex pipeline immunooncology program focused hardtotreat solid tumor well certain liquid tumor leukemia lymphoma believe multispecific antibody candidate simultaneously target several tumor antigen enable better control immune system activation expect tetraspecific laser program solid tumor enter clinic quarter first ind application indicated phil focused solid tumor deemed acceptable proceed fda immunooncology product advancing indenabling study target enter clinical study next year see exciting time opko execute strategy gain profitability bioreference health rightsizing diagnostic division profitable area activity advancing biopharmaceutical segment several program set enter clinic year turn call adam logal discus firstquarter financial result adamadam logal chief financial officer thank elia phil elia discussed busy start year realizing significant value underlying asset strengthening balance sheet convertible debt offering january reduced cash interest expense refinancing provided u flexibility align cash need research development investment debt maturity next five year addition used portion proceeds buy back million share common stock reducing outstanding share also announced agreement labcorp sale select asset competitive process completed allow u realign business operation focus core market test offering support path profitability bioreference still within review window federal trade commission diligently working profit plan bioreference ensure get break even profitability quickly possible labcorp deal first large step multifaceted plan moving financial result diagnostic segment reported revenue q million compared million period cost expense decreased million first quarter million period operating loss diagnostic segment million included approximately million nonrecurring cost related employee severance program associated effort return profitability depreciation amortization expense million million period respectively revenue included approximately million related book business subject sale agreement labcorp cost expense related business approximately million part transaction labcorp agreed offer employment impacted employee support business moving pharmaceutical segment revenue decreased million first quarter million comparable period revenue product including intellectual property international pharmaceutical business decreased million reflecting lower sale within israeli api business partially offset higher sale rayaldee revenue transfer ip million first quarter compared million quarter included upfront payment million merck result ebv vaccine agreement well million milestone payment partner rayaldee first quarter pfizer able substantially reduce cost manufacturing ngenla obtaining approval significant scaleup manufacturing process order support global launch ngenla turn pfizer revalued inventory hand december st amortized difference manufacturing cost first four month standard accounting policy result anticipated gross profit share first quarter le anticipated reported gross profit share pfizer million compare million period pfizer obtained significant payer access yous ngenla look forward continued execution global commercialization plan addition revenue includes approximately million underlying agreement barda offset rd underlying support expense program cost expense pharmaceutical segment million first quarter compared million period research development expense first quarter million compared million period quarter included nonrecurring million expense related payment sanofi portion upfront payment merck partially offsetting decrease increased activity modex development program resulting operating loss quarter ended march st million compared operating income million first quarter previously mentioned benefited million milestone payment received quarter amortization expense related intangible asset unchanged million period turning consolidated result first quarter reported operating loss million compared operating loss million quarter net loss period included approximately million related fair value change embedded derivative related convertible note issued january period recorded noncash unrealized gain investment genedx million respectively period result net loss first quarter million per share compare net loss million per share quarter looking ahead providing financial guidance following assumption pharmaceutical segment number factor continue impact gross profit share payment pfizer including revenue product sale genotropin ngenla global sale genotropin first quarter reported pfizer million pfizer separately reported sale ngenla however continued observe consistent prescription growth globally ngenla reported iqvia symphony adjusting expected accounting impact improved gross margin associated increased manufacturing scale ngenla revised estimated gross profit share million million versus previous estimate million million also assume stable foreign exchange rate exyous pharmaceutical business allow continued profitable growth rd expense second quarter reflect higher activity related modex program including cmc effort related initiation first immunooncology clinical trial portion increased activity continue funded barda agreement diagnostic segment timing closing labcorp transaction yet certain subject ftc review adjusted guidance remove business secondquarter estimate outlined working align business achieve cash flow breakeven run rate middle profitability run rate end year subject timing closing labcorp transaction work continues include consolidating geographic footprint rationalizing testing offering expect client mix improve cost structure appropriately support goforward strategy transition phase expect consistent core testing volume slight increase average price per patient collection amount due revenue cycle management initiative considering nonrecurring cost may result restructuring activity nonrecurring expense expect cost expense q decline approximately million approximately million without giving effect approximately million related asset part labcorp transaction result expect following second quarter total revenue million revenue service million including million asset related labcorp transaction revenue product sale million revenue million inclusive pfizer gross profit share estimate million expect secondquarter cost expense million excluding nonrecurring expense expense related restructuring bioreference also include approximately million rd expense range based timing certain cmc activity modex program well depreciation amortization expense million concludes prepared remark thank attention operator let u open call question question answer operatoryes thank operator instruction first question come maury raycroft jefferiesmaury raycroft jefferies analyst hi thanks taking question going start question related bioreference remaining bioreference service business sound like plan continue streamline optimize grow business aim get profitability labcorp deal close able provide clarity timing getting breakeven profitability longerterm strategy maximizing value service pharma part companyadam logal chief financial officer take first question maury thanks question timing u getting breakeven going tied labcorp transaction certainly waiting relates rest business actively working fixed cost face exiting certain facility currently help bring fixed overhead also continuing realign stated goal plan would executing u run rate cash cash flow breakeven midyear think still looking toward obviously ftc take longer expected could take longer otherwise path onmaury raycroft jefferies analyst got understood ngenla provide perspective clarity revised guidance change gross profit thereadam logal chief financial officer sure overall seen ngenla demand continue strong global basis pfizer market longest obviously continued best really change guidance accounting consequence revaluing inventory book flow gross profit share reflection strength program timing going realize benefit improved gross margin coming scaleupmaury raycroft jefferies analyst got understood maybe one question modex clinical asset specific catalyst year focused particular moving clinic know anything say study could see initial data thatelias zerhouni vice chairman president let gary line ceo modex answer specific question garygary nabel president chief executive officer modex therapeutic yes elia phil mentioned green light go moment setting site really looking bring patient trial think elia said comment hopeful happen end quarter working make happen soon possible term clinical result probably know whenever taking new immune therapy clinic start low dose dose escalate really safety reason plan come craft fda would expecting see data certainly efficacy least probably next year timeframe might expect see type resultsmaury raycroft jefferies analyst ok understood thanks taking question hop back queueoperatorthank next question come jeff cohen ladenburg thalmann companyjeffrey cohen ladenburg thalmann company analyst hi thanks taking question good afternoon end wondering could talk general paying additional study far couple expanded label mentioned pfizer yourselfadam logal chief financial officer way partnership work additional indication split cost pfizerjeffrey cohen ladenburg thalmann company analyst okgary nabel president chief executive officer modex therapeutic adult necessarily expecting additional study would pediatric basketjeffrey cohen ladenburg thalmann company analyst ok got full year anticipate barda reimbursement know called first quarter extrapolate thatadam logal chief financial officer would expect continue ramp jeff part reason rd number going getting ready cmc activity bump number reminder million revenue line expense line slightly le thatjeffrey cohen ladenburg thalmann company analyst yep ok got make sense adam clarify cash debt cash plus debt sideadam logal chief financial officer rightjeffrey cohen ladenburg thalmann company analyst adam logal chief financial officer rightjeffrey cohen ladenburg thalmann company analyst ok anticipated labcorp closing expecting end year sound like back half gross number right adam logal chief financial officer yes mean large unknown timing ftc clear ftc assuming clear ftc working quickly labcorp transactionjeffrey cohen ladenburg thalmann company analyst ok got feeling optimistic back half yearadam logal chief financial officer expectationjeffrey cohen ladenburg thalmann company analyst ok got think u thanks taking questionsadam logal chief financial officer thanks jeffoperatorthank next question come edward tenthoff piper sandlerted tenthoff piper sandler analyst great thank taking question first quick one adam mentioned cost guidance second quarter writing furiously get numberadam logal chief financial officer ted tenthoff piper sandler analyst adam logal chief financial officer ted tenthoff piper sandler analyst ok great super helpful kind higherlevel question appreciating gary elia saying multispecific antibody getting moving think first one hematologic cancer mistaken solid tumor higher level ultimately expect different modex asset stuff barda could partnered expect partnership like merck ebv deal expect keep cancer stuff generate clinical data next year higherlevel commentary sort plan thank youelias zerhouni vice chairman president happy forgive background noise think solid tumor molecule entering clinic quarter liquid tumor molecule actually discussing several party interested think grand scheme thing platform right actually two platform vaccine one multispecific one eliciting lot interest interested partnering especially research collaboration funded third party could develop target enter larger portion market could afford want leverage platform ability u result result already ebv phase multispecific data hopefully one think going generate momentum collaboration partnership licensing think increase bandwidth stop gary much saygary nabel president chief executive officer modex therapeutic yeah think said well elia would say ted open whatever make sense term advancing product approval getting patient think advantage platform take individual product partner third party reserve may higher value easier path forward commercialization take internally well end day suspect probably partner develop internally open collaborationted tenthoff piper sandler analyst well think make lot sense think different factor agent engineer multispecific antibody big oncology group really multiplex combinatorial analysis make lot sense lot guy think would really able empower bigger player looking way combine different mechanism really appreciate saying partnering potential platform thank yougary nabel president chief executive officer modex therapeutic sureoperatorthank next question come yale jen laidlaw companyyale jen laidlaw company analyst good afternoon thanks taking question two question regard modex product enter clinic soon first one evv virus vaccine question also competitor moderna also developing vaccine target question least theoretical ground compare moderna followup questionelias zerhouni vice chairman president well answer simple jen mean better let gary give specific kiddinggary nabel president chief executive officer modex therapeutic well take step back moderna actually delivering mrna almost gene product managed engineer onto ferritin nanoparticle would say good patient actually good thing one product tested one never know perform real world think like platform fact protein platform using adjuvant welldescribed safety profile look favorable human preclinical data nonhuman primate animal model strong following pretty wellprescribed path nice set immunogen think great biomarkers looking viral load immune response virus feel pretty good product really want get detail alternative program say obvious using different platform using mrna platform advantage term going fast unknown particularly regard side effect therapy begin treat patient vaccine issue become important way ordain crystal ball work better feel pretty good platform partnership merck real deep bench expert knowledge expand trial expand reach vaccine would ultimately like address cancer cancer aspect vaccine think best right nowyale jen laidlaw company analyst ok great helpful lot detail maybe one term could give u detail study design maybe target pursued tritarget antibody thanksgary nabel president chief executive officer modex therapeutic yes formally disclosed target disclose near future probably within next week line enroll first patient tell picked two cell surface marker found number solid tumor actually list malignancy express two antigen include lung breast prostate pancreatic list go fairly large number tested initial stage look variety tumor type looking sign tumor type might seeing efficacy time bear focus tumor type seeing efficacy expand trial tumor typesyale jen laidlaw company analyst ok great helpful congrats move program groundgary nabel president chief executive officer modex therapeutic thank excited see get patientsoperatorthank next question come yi chen hc wainwrightyi chen hc wainwright company analyst thank taking question follow mdx phase solid tumor trial allcomer solid tumor trial correct many patient intend enroll trialgary nabel president chief executive officer modex therapeutic trial broken part phase phase b would say phase group look multiple different type point begin drill one activity expect able make decision approximately patient first includes dose escalation go slowly agnostic tumor type reach think close therapeutic level assuming see side effect would preclude expansion would treat larger numberyi chen hc wainwright company analyst clarify say result phase trial available gary nabel president chief executive officer modex therapeutic really say would available said probably next year said earlier would stand take get point think therapeutic dose enroll sufficient patient follow period time expecting see even early efficacy data certainly safety data think end year tell u dos well tolerated patient expect begin start seeing signal well next yearyi chen hc wainwright company analyst got could give u idea many oncology candidate intend bring clinical stage development end gary nabel president chief executive officer modex therapeutic would say range two four think likely two clinic next year depending partnership may opportunity advance another twoyi chen hc wainwright company analyst ok partnership likely need generate phase level proof concept data materialize partnershipgary nabel president chief executive officer modex therapeutic know think elia would like respondelias zerhouni vice chairman president wanted clarify different oncology area oncology start patient need phase data generate partnership need basket trial demonstrable result phase b beginning need need area need complete phase attract major partner would like strategic buyer know agree garygary nabel president chief executive officer modex therapeutic much agree think often oncology begin see signal phase instance really depends appetite partner internal team term point really want make transition would say safe answer somewhere phase phase yi chen hc wainwright company analyst got thank youoperatorthank next question come michael petusky barrington researchmike petusky barrington research analyst want ask rayaldee guy indicating last month least several month maybe got think got data got evidence product may slow ckd progression curious mean sale folk able share data evidence nephrologist even kind anecdotal reaction yes really compelling may really matter mean give sense sense could really unlock product going forward thankselias zerhouni vice chairman president expand mean clear data generated year telling realworld evidence well data could delay onset dialysis six month term reception publishing obviously presented kols nephrologists really make difference therapy secondary hyperthyroidism shown ability show also biomarkers really indicate patient one really need rayaldee delay onset dialysis ckd yes sale force yes talking nephrologists see lot latestage ckds likely go dialysis also think valid ckd patient story evolution think reinforces point treating secondary hyperthyroidism patient impact evolution disease one question always change outcome answer far data reviewed going publishedmike petusky barrington research analyst add followup term ok get data published start talking doc mean long thing sometimes seem move much slower logically seem like term changing behavior prescribing behavior mean kind thing really missionary effort matter year rather quarter really change behavior data compellingelias zerhouni vice chairman president absolutely think right question mean medicine medicine pattern clinical guideline take time develop mean talking year two make guideline well using guideline rapid process depending strength reception community pathologist deal may faster slower matter quarter two take time developmike petusky barrington research analyst right good thank youoperatorthank concludes questionandanswer session would like return floor back dr phillip frost closing commentsphillip frost chairman chief executive officer want thank everybody participating good question discussion look forward together end next quarteroperatoroperator signoff duration minutescall participantsyvonne briggs investor relationsphillip frost chairman chief executive officerelias zerhouni vice chairman presidentadam logal chief financial officermaury raycroft jefferies analystgary nabel president chief executive officer modex therapeuticsjeffrey cohen ladenburg thalmann company analystted tenthoff piper sandler analystyale jen laidlaw company analystyi chen hc wainwright company analystmike petusky barrington research analyst opk analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy